Back to school

Rice University teams up with workforce accelerator to create a first-of-its-kind fintech bootcamp

Trilogy Education and Rice University have joined forces for a new program. Photo courtesy of Rice University

As Rice University's campus continues to welcome back its students for a new year, the administration has big news about a new, innovative program to share.

Rice University's Glasscock School of Continuing Studies has partnered with New York-based workforce accelerator, Trilogy Education, to provide the first fintech boot camp on a college campus, according to a representative from the company.

"Technology skills are becoming foundational for many roles in the finance, energy and life science sectors," says David Vassar, assistant dean of professional and executive programs at the Glasscock School, in a news release. "We have partnered with Trilogy Education to bring to market a boot camp that prepares students to use their technical skills in a wide variety of fintech applications, from robo-advising to cryptocurrency. Whether you are already in finance or are looking for a way to transition into the industry, this program will prepare you to build a meaningful career in the fast-moving world of fintech."

Rice University FinTech Boot Camp is a 24-week program, and the inaugural class began in July. Enrollment for the next round is open from now until November 18. The program will provide students with core coding languages and technical tools that are crucial in the industry as well as pertinent technologies like machine learning and cryptocurrency. The participants will also have career-planning services and will receive a Certificate in Financial Technology from Rice.

The financial industry is booming in Houston, per the release, and companies are in competition for trained talent. Institutions like U.S. Bancorp and JPMorgan Chase have more coding positions open than Apple and Google, the release reveals, and according to data from Burning Glass, the country has added over 1.5 million fintech jobs in the past 8 years.

"The Rice University FinTech Boot Camp comes at a critical moment of need as the city of Houston transforms itself into a national hub for enterprise technology," says Robert Bruce, dean of the Glasscock School, in the release. "We've seen several fintech companies choose Houston to open new office locations and a rising demand from our longstanding industries like energy and manufacturing to transform themselves into technology and data-driven businesses."

Last year, the school launched its first boot camp in partnership with Trilogy. The Rice University Data Analytics Boot Camp has recently grown to expand to a new location in the Energy Corridor, the release states.

"Rice University's Glasscock School of Continuing Studies is playing an important role in building the digitally skilled workforce that Houston needs to support a growing innovation economy," says Dan Sommer, CEO and founder of Trilogy Education, in the release. "The Rice University FinTech Boot Camp will help working adults in Houston capitalize on the exploding demand for technology and data skills and spur additional investment in fintech throughout the region."

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News